PCVX Vaxcyte, Inc.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business model: Development and commercialization of proprietary pneumococcal conjugate vaccines
• • New manufacturing agreement with Lonza Ltd effective January 2026 for development and commercial supply of vaccine components
• • Strategic move to secure long-term manufacturing capacity with fees in mid- to high-eight-figures Swiss Francs annually through 2038 plus renewals
• • License received from Lonza: perpetual, irrevocable, royalty-free rights to use Lonza’s intellectual property related to product and manufacturing process
• • Contract includes termination rights with termination fees in low-eight-figures Swiss Francs, ensuring operational flexibility and risk mitigation

Risk Factors

• • Cybersecurity breach risk with potential regulatory fines, investigations, operational disruptions, and reputational harm
• • SVP IT with 30+ years experience leads cybersecurity risk management and incident response
• • Cybersecurity incident escalation to President and CFO, with audit committee oversight and quarterly reporting

Management Discussion & Analysis

• • No revenue generated in FY 2026 as Vaxcyte is clinical-stage; net losses $766.6M in 2025 vs $463.9M in 2024 vs $402.3M in 2023
• • Operating losses increased due to advancing clinical trials and manufacturing scale-up; cash, equivalents, investments $2.44B as of Dec 31, 2025
• • Best performing pipeline: VAX-31 Phase 3 adult PCV program initiated with ~3,560 adults dosed; FDA breakthrough therapy designation expanded to pneumonia prevention
• • Capital raise: February 2026 public offering gross proceeds $632.5M from 12.65M shares at $50 each
• • Forward outlook: Phase 3 data awaited late 2026 (adult) and first half 2027 (infant); planning BLA submission post Phase 3; risks include development timelines and regulatory approvals

What are the latest PCVX SEC filings in 2026?

Vaxcyte, Inc. (PCVX) has filed a 10-K annual report on February 24, 2026, a 10-Q quarterly report on May 6, 2026, an 8-K current report on August 5, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did PCVX file its most recent 10-K annual report?

Vaxcyte, Inc. (PCVX) filed its most recent 10-K annual report on February 24, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view PCVX 10-Q quarterly reports?

Vaxcyte, Inc. (PCVX)'s most recent 10-Q quarterly report was filed on May 6, 2026. SignalX displays every PCVX 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has PCVX filed recently?

Vaxcyte, Inc. (PCVX)'s most recent 8-K was filed on August 5, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find PCVX insider trading activity (Form 4)?

SignalX aggregates every PCVX Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does PCVX file with the SEC?

Vaxcyte, Inc. (PCVX) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new PCVX filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Vaxcyte, Inc. (PCVX).

What is PCVX's SEC CIK number?

Vaxcyte, Inc. (PCVX)'s SEC CIK (Central Index Key) number is 1649094. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1649094 to look up all PCVX filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find PCVX return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Vaxcyte, Inc. (PCVX) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.